Qiagen, LLC

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$2.2Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
1,993clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $30K
2020 $194K
2021 $275K
2022 $482K
2023 $484K
2024 $407K
2025 $368K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Hematology & Oncology $1.0M
Medical Oncology $447K
Internal Medicine $286K
Neurology (Psychiatry & Neurology) $175K
Surgical Oncology $108K
Hospitalist $53K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Ross Levine New York, NY Hematology & Oncology $752,965.46
Richard White New York, NY Medical Oncology $227,500.00
Mikael Rinne Boston, MA Neurology (Psychiatry & Neurology) $175,200.00
Loyce Kawamura San Francisco, CA Internal Medicine $162,125.46
David Barbie Boston, MA Hematology & Oncology $138,000.00
Robert Lindsley Boston, MA Medical Oncology $115,011.00
Andrew Lane Boston, MA Hematology & Oncology $111,750.00
Ryan Corcoran Boston, MA Internal Medicine $108,000.00
Thanh Barbie Boston, MA Surgical Oncology $108,000.00
Cesar Castro Boston, MA Medical Oncology $103,500.00

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.